Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion
Am J Respir Crit Care Med
.
2019 Feb 1;199(3):390-392.
doi: 10.1164/rccm.201809-1776LE.
Authors
Kenneth R Chapman
1
,
John R Hurst
2
,
Robert B Fogel
3
,
Pascal Pfister
4
,
Konstantinos Kostikas
4
,
Jadwiga A Wedzicha
5
6
Affiliations
1
1 University of Toronto Toronto, Ontario, Canada.
2
2 University College London London, United Kingdom.
3
3 Novartis Pharmaceuticals Corporation East Hanover, New Jersey.
4
4 Novartis Pharma AG Basel, Switzerland.
5
5 Imperial College London London, United Kingdom and.
6
6 Editor-in-Chief, AJRCCM.
PMID:
30335471
DOI:
10.1164/rccm.201809-1776LE
No abstract available
Publication types
Letter
Comment
MeSH terms
Double-Blind Method
Humans
Indans*
Pulmonary Disease, Chronic Obstructive*
Quinolones*
Substances
Indans
Quinolones
indacaterol